Research programme: telomere oligonucleotides - Micromet/SemaCo

Drug Profile

Research programme: telomere oligonucleotides - Micromet/SemaCo

Latest Information Update: 18 Mar 2008

Price : $50

At a glance

  • Originator SemaCo
  • Developer Micromet Inc
  • Class Oligonucleotides
  • Mechanism of Action Telomerase activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 May 2006 Micromet AG has merged with CancerVax Corporation to form Micromet Inc
  • 03 Sep 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
  • 19 Mar 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top